|1.||Chen, Xiaoyuan: 7 articles (08/2014 - 03/2005)|
|2.||Kharitonova, M V: 7 articles (04/2013 - 08/2007)|
|3.||Kravchenko, M S: 7 articles (04/2013 - 08/2007)|
|4.||Iezhitsa, I N: 7 articles (04/2013 - 08/2007)|
|5.||Nissim, I: 7 articles (12/2001 - 03/2000)|
|6.||Spasov, A A: 6 articles (04/2013 - 08/2007)|
|7.||Phillis, J W: 6 articles (09/2003 - 01/2000)|
|8.||O'Regan, M H: 6 articles (09/2003 - 01/2000)|
|9.||Liu, Bin: 5 articles (02/2015 - 03/2011)|
|10.||Studneva, I M: 5 articles (11/2008 - 01/2004)|
|1.||Body Weight (Weight, Body)
12/01/2011 - "A carrier control group was administered diet with no added NAA and a comparative control group was given aspartate (ASP), the constituent amino acid of NAA, at a target dose of 500 mg/kg of body weight/day. "
11/01/1997 - "Newborn male and female rat pups were injected with either 2 mg or 4 mg monosodium aspartate (MSA)/g body weight or diluent on alternate days for the first 9 days of life. "
01/01/1988 - "When carbohydrate (1 g/kg body weight) was administered simultaneously no lesions were detected in mice administered 750 mg/kg body weight aspartate, while 30.1 +/- 14.2 necrotic neurons/section were noted at 1000 mg aspartate/kg body weight. "
11/01/1987 - "The addition of 10 mg APM/kg body weight to the beverage had no significant effect on plasma aspartate concentration. "
02/01/1985 - "A modest, but significant effect of carbohydrate was noted on the mean peak plasma aspartate levels in animals administered 1000 mg/kg body weight aspartate (P less than 0.05, Student's t-test). "
|2.||Type 1 Diabetes Mellitus (Autoimmune Diabetes)
12/01/1992 - "A single aspartate is not protective against insulin-dependent diabetes mellitus in Hispanic subjects."
11/01/1992 - "DNA sequence analysis of class II HLA from Caucasian and black patients with type 1 (insulin-dependent) diabetes mellitus has suggested that aspartic acid at position 57 (Asp 57) of the DQ beta chain provides protection against insulin-dependent diabetes mellitus (IDDM). "
02/01/1990 - "Therefore, the Asp 57 hypothesis that the presence of an aspartic acid at position 57 of DQ beta-chain provides protection against developing IDDM is not tenable for Japanese IDDM patients. "
01/01/2005 - "The aspartic acid at position 57 in the DQB1 molecule as in DQB1*0401 is reported to play a role in the resistance to IDDM. "
10/01/1999 - "We formulate the hypothesis that suceptibility to IDDM is not only explained by the absence of Aspartate 57 (negative charge) from pocket 9 of DQB1 (P9DQ), but also by the presence of an electric charge (+/- vs. neutral), generated by residues 70, 71 and 74 in pockets 4 of DRB1 (P4DR) and DQB1 (P4DQ) molecules. "
10/01/2013 - "Hippocampal cysteinyl aspartate-specific protease-3 (caspase-3) activity, nitrite/nitrate contents (NOX), as well as COX-2 immunoreactivity in the hippocampal Cornu Ammonis 1 (CA1) subregion were dramatically increased 24 hours after global ischemia. "
01/01/2013 - "Aspartate release was prominently enhanced by both ischemia and K(+) stimulation in the adult cerebral cortex. "
08/01/2007 - "Aspartate application accelerated the rates of FC-induced mitochondrial depolarization, and, at 1 mmol/L, induced astrocytic death, suggesting that strong energetic demands during ischemia can compromise astrocytic function and viability."
08/01/2004 - "Tissue final aspartic acid level, however, was doubled by ischemia. "
08/01/2003 - "Aspartate immunoreactivity was significantly elevated at 4 and 6 min post-ischemia in neurons, prior to a change in any other amino acid. "
01/01/2016 - "Aspartate β-hydroxylase (ASPH) was found to link these upstream growth factor signaling pathways to downstream Notch activation in tumor tissues. "
04/01/2014 - "Our results indicated that aspartate metabolism is a significant and differentiable metabolic pathway of HCC compared with non-tumor liver (p value < 0.0001). "
05/01/2012 - "Aspartate-β-hydroxylase (ASPH) is an attractive cellular target since it is a highly conserved transmembrane protein overexpressed in both murine and human HCC tumors, and promotes a malignant phenotype as characterized by enhanced tumor cell migration and invasion. "
03/01/2008 - "Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity."
01/01/2001 - "Structural variations of the L-aspartic acid substructure of (S)-N-3-phenoxycinnamoylaspartic acid dimethyl ester which shows a selective antiproliferative activity against THP-1 tumor cells, demonstrated that the L-aspartic acid moiety is absolutely mandatory for antiproliferative activity as well as for selectivity."
12/01/1998 - "Higher doses (100 nmol/0.5 microl) of 2-a-3-arsonopropionate the analogue of aspartate increased the generalized seizure threshold by 40% (P < or = 0.025), while 2-a-4-arsonobutyrate was not effective even at high doses."
10/01/1998 - "Seizures induced with Thiosemicarbaside, Pentylenetetrasole, N-methyl-D,L-aspartate were used as models. "
03/01/1996 - "On the other hand, N-methyl-DL-aspartate (NMDLA; 300 mg/kg or 350 mg/kg, IP) induced clonic seizure, but tonic seizure was not always noted. "
08/01/1994 - "Thus, enhanced aspartate release precedes the onset of EL seizures and may be related to the cause rather than to the effects of seizure activity."
04/21/1994 - "The facilitating or antagonizing effects of polyamine analogues on N-methyl-DL-aspartate (NMDLA)-induced seizures were investigated using mice. "
|1.||Glutamic Acid (Glutamate)
|4.||Glycine (Aminoacetic Acid)
|9.||L-Lactate Dehydrogenase (Lactate Dehydrogenase)
|1.||Transplantation (Transplant Recipients)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)